Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
(2015) In European Journal of Haematology- Abstract
- Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by... (More)
- Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7844335
- author
- Jerkeman, Mats LU and Lindén, Ola LU
- organization
- publishing date
- 2015-08-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Haematology
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:26256458
- scopus:84940055412
- wos:000374147300012
- pmid:26256458
- ISSN
- 1600-0609
- DOI
- 10.1111/ejh.12646
- language
- English
- LU publication?
- yes
- id
- bb4778b6-2f94-4066-9216-85f1011a7cc5 (old id 7844335)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26256458?dopt=Abstract
- date added to LUP
- 2016-04-04 08:38:31
- date last changed
- 2022-02-06 00:10:42
@article{bb4778b6-2f94-4066-9216-85f1011a7cc5,
abstract = {{Multicentric Castleman's disease (MCD) is an uncommon lymphoproliferative disorder, often associated with a clinically aggressive behavior. No standard treatment has been established, but patients are usually treated with lymphoma-type regimens such as rituximab or combination chemotherapy. Recently, immunotherapies targeting IL-6 have proven effective and have been approved for this indication. However, these agents require long-term administration. Here, we describe the clinical course of two patients, refractory to rituximab and chemotherapy, showing long-term remission (18 and 24 months), following an induction phase with tocilizumab (an anti-IL-6 receptor antibody) and a consolidative phase with high-dose melphalan accompanied by autologous stem cell support. This may prove to be an effective option for this group of patients with an orphan disorder.}},
author = {{Jerkeman, Mats and Lindén, Ola}},
issn = {{1600-0609}},
language = {{eng}},
month = {{08}},
publisher = {{Wiley-Blackwell}},
series = {{European Journal of Haematology}},
title = {{Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.}},
url = {{https://lup.lub.lu.se/search/files/5189334/8868317.pdf}},
doi = {{10.1111/ejh.12646}},
year = {{2015}},
}